Avalo Therapeutics, INC. (AVTX) — 10-Q Filings

All 10-Q filings from Avalo Therapeutics, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Avalo's Losses Mount Amid Soaring R&D Costs, Cash Dwindles — Nov 6, 2025 Risk: high
Avalo Therapeutics, Inc. (AVTX) reported a significant net loss of $64.5 million for the nine months ended September 30, 2025, a substantial increase from the n
Avalo Therapeutics Reports Zero Revenue, Deepening Losses in Q2 — Aug 7, 2025 Risk: high
Avalo Therapeutics, Inc. (AVTX) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net
Avalo Therapeutics Files Q1 2025 10-Q — May 12, 2025 Risk: medium
Avalo Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Cerecor Inc., is based in Wayne, PA. The filing det
Avalo Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
Avalo Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Cerecor Inc., reported its financial status. Ke
Avalo Therapeutics Files Q2 2024 10-Q — Aug 12, 2024 Risk: medium
Avalo Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Cerecor Inc., reported financial results and operati
Avalo Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: low
Avalo Therapeutics, Inc. (AVTX) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Avalo Therapeutics, Inc. filed a 10-Q report for the quarterly per

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX